- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03203044
Impact of Soylent Consumption on Human Microbiome Composition
Study Overview
Detailed Description
After collecting this preliminary information, main study participants will be chosen based on our described inclusion/exclusion criteria. We will distribute eight fecal sampling kits to each participant in preparation for the study. The study duration is 10 days and consists of three phases:
In Phase A, participants will adhere to their regular diet for two days. This initial condition provides a baseline of each participant's unique microbiome, acting as an internal control.
In Phase B, a subset of the participants, which will be chosen by random drawing from a box, will switch to an all-Soylent diet. During this phase, they will consume five bottles of Soylent 2.0 daily for four days (one for breakfast, two for lunch, and two for dinner), fully meeting a 2000kcal diet and all recommended nutritional daily values. The remaining participants will retain their regular diets for four days. These individuals act as a control for the daily variance of microbiome fluctuations.
In Phase C, participants will return to their regular diets for four days, after which the study will conclude.
For the duration of the study, participants will log their diets and bowel movements electronically on a daily basis. A printout of the Bristol Stool Chart will be provided at the beginning of the study to each participant. Each entry will be logged through a Google Form and labeled with each individual's participant ID, which will link them to their responses. The link will include name, email, and phone number. The completed forms are only accessible through a single Google account, which is password protected, encrypted, and only accessible by the investigators. In addition, participants will sample their microbiomes using the uBiome gut kits on the following days: 1, 2, 3, 4, 5, 6, 7, and 10. Sampling is done by swabbing used toilet paper after bowel movements. Participants will seal the samples in the kits and mail them to uBiome with the included prepaid postage. The investigators will not come into direct contact with any of the samples.
All electronic logs and samples will be labeled with each participant's unique participant ID. The link between each participant and their sample kits will be maintained on the participant reference sheet kept by the researchers. uBiome will not have access to this link.
Once all data in the study has been received, the participant reference sheet will be shredded and all of the data will become unidentifiable. While Soylent has no documented instances of causing physical complications to consumers, if any participant feels unwell during any point in the study, they are encouraged to cease participation and contact their primary care doctor for guidance.
Results from the uBiome gut kits will be received in about four to six weeks. uBiome will share the data individually with each participant (if participants chose to create an account and register their kits as stated above) and in bulk with the researchers. For participants that did not register their kits with uBiome, the data generated from those participants will only be sent to the researchers. The data consists of sequencing data labeled with each kit's serial number. We will then correlate our electronic log data with the uBiome sample data for further analysis. The data generated in this study is in no way intended for medical diagnosis of any kind. uBiome's website states the following: "It's important to be aware that uBiome is designed to be a tool for personal research, NOT a diagnostic tool. You won't find any predictions about your future health. And your results will not diagnose any medical condition."
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- The subject population will consist of undergraduate UC Berkeley students.
Exclusion Criteria:
- Dietary allergies or sensitivities to Soylent 2.0 ingredients
- Vulnerable individuals as defined by Committee for Protection of Human Subjects guidelines
- Individuals with health issues
- Individuals who take antibiotics, probiotics, alcohol, or supplements.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Regular Diet Arm
Maintains a regular diet for the duration of the study.
|
|
|
Experimental: Soylent Diet Arm
Receives a Soylent dietary intervention on days 3-6 of the study.
|
A diet of five servings of Soylent 2.0 liquid meal-replacement drink per day and water as needed.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Changes to gut microbiome composition as a result of an interventional Soylent diet
Time Frame: Days 3-6 of the study
|
Days 3-6 of the study
|
Collaborators and Investigators
Investigators
- Principal Investigator: Adam P Arkin, PhD, Professor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- soylentmicrobiomeproject
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Gut Microbiota
-
Shanghai 10th People's HospitalRecruitingGut MicrobiotaChina
-
University of California, DavisCompletedGut MicrobiotaUnited States
-
TCI Co., Ltd.Completed
-
University of OttawaCompletedInsulin Resistance | Glucose Intolerance | Insulin Sensitivity/Resistance | Insulin Sensitivity | Gut Microbiota | Intestinal Permeability | Glucose Homeostasis | Gut Microbiota Dysbiosis and Nutrition | Low-grade Inflammation | Glucose and Insulin Response | Gut Microbiota Dysbiosis | Gut Microbiota Diversity... and other conditionsCanada
-
University of AberdeenNHS GrampianCompletedGut MicrobiotaUnited Kingdom
-
University of ReadingCompleted
-
Biofortis, Merieux NutriSciencesLonza Inc.CompletedGut MicrobiotaUnited States
-
Kosin University Gospel HospitalCompleted
-
Pennington Biomedical Research CenterWithdrawnGut Microbiota
Clinical Trials on Soylent and water diet
-
University of ParmaUnknownHypertension | Obesity | Overweight | Urinary StonesItaly
-
Virginia Polytechnic Institute and State UniversityRecruiting
-
Second Affiliated Hospital, School of Medicine,...Completed
-
Gadjah Mada UniversityEnrolling by invitationInsulin ResistanceIndonesia
-
University of CologneCompleted
-
University of AarhusCompletedIleostomy - Stoma | Intestinal FailureDenmark
-
Kubra KAYACompleted
-
George Washington UniversityCompletedObesity | Diabetes
-
Simon Fraser UniversityRecruitingSyncope | Orthostatic Hypotension | Vasovagal SyncopeCanada
-
Jonsson Comprehensive Cancer CenterNational Cancer Institute (NCI)Active, not recruitingLocally Advanced Head and Neck CarcinomaUnited States